



DRUG DISCOVERY

Winning R&D Productivity Strategies

Exploiting innovation, licensing and outsourcing opportunities

By Sarah Riley

 [Table of Contents](#)

Sarah Riley

Sarah Riley is an analyst within the healthcare function of Business Insights. She has a PhD in physiology from King's College, London and is an expert in autoimmune diseases and cardiology. She has previously worked on commercial analyses of the generics market, the future of the diabetes market and pharmaceutical licensing strategies.

Copyright © 2006 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Winning R&D productivity strategies

Executive Summary	10
Introduction	10
New technologies in R&D	11
Project and portfolio management	12
Licensing and partnerships in R&D	13
Resource management	14
Monitoring performance of strategies implemented	15
Chapter 1 Introduction	18
Summary	18
Introduction	19
R&D	19
Decrease in R&D productivity	20
Industry opinion of R&D productivity	22
Risk and the commercial market in drug discovery	24
Challenges and causes of decline	26
Cost of drug development	27
Innovation and attrition	28
Regulatory burden	31
Size and scale of operations	32
Clinical development times	33
The key issues affecting R&D today	35
Opportunities and how to increase productivity	36
Responses to the crisis	38
Short-term	38
Long-term	38
Big Pharma emerging from the R&D productivity crisis	39

Chapter 2 New technologies in R&D 42

Summary	42
Introduction	43
The future of innovative technologies in R&D	45
Integration of technologies in the R&D process	45
Comparison of technologies in the R&D process	45
Technologies to increase the number of targets in drug discovery	47
Array technology	47
Biomarkers	51
Stem cells	52
Technologies for decreasing costs and development times	52
RNAi	52
Microfluidics	54
Toxicogenomics/ADMETox	55
High through-put screening	57
Technologies for decision making and optimization	57
Bioinformatics	57
Chemogenomics	59
Pharmacogenomics	60
The move towards targeted therapies	62
Conclusions and key points	63

Chapter 3 Project and portfolio management 66

Summary	66
Introduction	67
Why use project and portfolio management in R&D?	67
Challenges to project and portfolio management	68
Portfolio management	68
The R&D portfolio	68
The portfolio management process	69
Reviews and evaluations	69
Decision making and strategic alignment	71
Resource management	72
Portfolio management in action	72
Sanofi-Aventis	72
Genentech	73
Lundbeck	74
Project management	75
The project management process	75
Value and risk profiles	76
Financial evaluation	77

R&D Project management in action	78
Schering AG	78
AstraZeneca	79
Dr Reddy's	80
Conclusions and key points	81

Chapter 4 Licensing and partnerships in R&D 84

Summary	84
Introduction	85
Licensing and collaborations	85
The licensing process	85
Licensing trends	86
Multi product deals, and long term collaborations	87
Increased number and average value of licensing deals	91
Biotech as a licensing partner	91
Oncology is the dominant therapy area by number of deals	93
Licensing deals for later stage drugs	94
Out-licensing	95
In-licensing	95
Biogen Idec	96
Novartis	96
Collaborations	97
Curis	98
Roche	98
Future of licensing and collaborations	99
Outsourcing	99
Out-sourcing to increase R&D productivity	99
Impact of mega-mergers on productivity	100
Conclusions and key points	101

Chapter 5 Resource management 104

Summary	104
Introduction	105
Management and integration of deals in drug discovery	105
Alliance management	105
Managing partnerships	106
M&A	106
Timelines and preventing overruns	107
Organizational and operational issues in drug discovery	108

List of Figures

Figure 1.1:	R&D expenditure versus annual NME approvals, 1995-2005	21
Figure 1.2:	Total number of drug launches in the US, 1945-2004	22
Figure 1.3:	Industry opinion of R&D productivity over time	23
Figure 1.4:	Industry opinion of current R&D productivity in the Biopharma market	24
Figure 1.5:	Managing risk in drug development	25
Figure 1.6:	Industry opinion of the significance of challenges to R&D productivity, 0 = No significance 3 = Very significant.	27
Figure 1.7:	US drug pipeline is increasing novel	29
Figure 1.8:	Attrition rates by novelty status, current status of INDs filed 1996-1998	30
Figure 1.9:	Key reasons for attrition in drug discovery, 2003	31
Figure 1.10:	“Effective” patent life	34
Figure 1.11:	Increasing clinical development times	35
Figure 2.12:	Potential cost savings per drug using genomics (\$m)	43
Figure 2.13:	Integration of technologies in the R&D process	45
Figure 2.14:	Comparison of innovative technologies in R&D	46
Figure 2.15:	Industry opinion of how innovative technologies will affect R&D productivity over the next 5-10 years	47
Figure 2.16:	Microfluidics, features, benefits and applications	54
Figure 2.17:	Integration of databases within the discovery process	59
Figure 3.18:	The portfolio management process	70
Figure 3.19:	Risk assessment in practice	76
Figure 3.20:	An example of project management commissioning at Schering AG	78
Figure 4.21:	The pharmaceutical licensing process	86
Figure 4.22:	Number of top 10 pharmaceutical company licensing deals by deal type, 2001-2005	88
Figure 4.23:	Number of top 10 biotech company licensing deals by deal type, 2001-2005	89
Figure 4.24:	Industry opinion of change in the number of licensing/partnering deals in the last 5 years	90
Figure 4.25:	Industry opinion of change in the number of licensing/partnering deals in the next 5 years	90
Figure 4.26:	Average value of top 10 pharmaceutical company licensing deals, 2001-2005	91
Figure 4.27:	Number of top 10 pharmaceutical and biotech company licensing deals by partner, 2001-2005	92
Figure 4.28:	Proportion of product-based licensing deals by therapy area, 2001-2005	93
Figure 4.29:	Number of biotech R&D licensing deals by development stage, 2001-2005	94
Figure 4.30:	Licensing process at Novartis	97
Figure 4.31:	No economies of scale in pharmaceutical R&D	101
Figure 5.32:	Vision of networked pharma in 2016	110
Figure 5.33:	Wyeth’s R&D productivity model, 2001	111
Figure 5.34:	Advantages and disadvantages of inhouse, outsourced and collaborative R&D	114
Figure 5.35:	Industry opinion of the most productive method of conducting R&D	115
Figure 5.36:	Industry opinion of attractiveness of countries/regions for R&D outsourcing. 1 = very unattractive, 5 = very attractive. Response average shown	116
Figure 6.37:	Major reasons to implement monitoring of R&D processes	125
Figure 6.38:	Markers of productivity	127
Figure 7.39:	R&D productivity survey respondents by company focus	134

List of Tables

Table 1.1:	R&D by function, PhRMA member companies, 2004	28
Table 2.2:	Companies involved in array technologies, A-L	49
Table 2.3:	Companies involved in array technologies, M-Z	50
Table 2.4:	siRNA-based drugs and therapies	53
Table 2.5:	Biotech providers of commercial ADMETox software	56
Table 3.6:	Risk factors in project management	77
Table 5.7:	Reasons for time and budget overruns	108
Table 5.8:	Mean clinical development times in months, based on 400 protocols, 2000	114
Table 5.9:	US R&D scientific, professional and technical personnel by function, PhRMA companies: 2004	117
Table 5.10:	US FDA new drug application data generated from India	119